Innovacyn, a provider of human and animal healthcare products, has added Vetericyn VF Ophthalmic Wash and Vetericyn VF Otic Rinse to its professional-strength animal healthcare line.
Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA).
Evotec has entered into an oncology research and development agreement with Roche to organize multiple protein-activity based biomarker programs for Roche's therapeutic antibodies or small molecule inhibitors under development.
Radius Health, Inc. and 3M Drug Delivery Systems announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius’ novel, proprietary PTHrP (parathyroid hormone-related protein) analog, for the treatment of osteoporosis.
RxMD has collaborated with GlycoRegImmune (GRI) to develop new treatments by using GRI's novel natural killer (NK) T cell targeted technologies for autoimmune, inflammatory and neurodegenerative conditions.
Evotec AG announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. The two companies will work together in a seamless fashion to provide existing and new clients access to their complementary drug discovery platforms for the identification and development of new therapeutics to treat CNS disorders.
Amgen announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone. Full results of the '147 study were presented for the first time today in a late-breaking plenary session at the American Urological Association (AUA) 2011 Annual Meeting in Washington, D.C.